About Careers MedBlog Contact us

Successful Clinical Trials For New Rheumatoid Arthritis Drug

by Tanya Thomas on June 29, 2009 at 10:47 AM
Font : A-A+

 Successful Clinical Trials For New Rheumatoid  Arthritis Drug

Researchers have found that a new drug in development for the treatment of rheumatoid arthritis has been found to be well tolerated and effective in a clinical trial.

The trial of the drug called masitinib was carried out by researchers from several French hospitals. It involved 43 patients with arthritis resistant to current treatments.


Reporting their findings in BioMed Central's open access journal Arthritis Research and Therapy, the researchers have revealed that treatment with masitinib significantly reduced the severity of active arthritis.

"In choosing which interventions to use for the management of rheumatoid arthritis, it is important to recognise that treatment should aim to keep the disease in remission and not be used intermittently to manage exacerbations. We are encouraged from this study that masitinib not only appears to be effective, but that within the first 3 months of treatment the worst of its side-effects were over, possibly making it suitable for long-term treatment regimens," said Olivier Hermine, one of the researchers.

"The results of this study also help establish the critical role of mast cells in the pathogenesis of rheumatoid arthritis and demonstrate their viability as a therapeutic target. There is sufficient compelling evidence to warrant further placebo-controlled investigation," he added.

The researchers have revealed that masitinib inhibits the activity of mast cells, a component of the immune system thought to be involved in the pathogenesis of rheumatoid arthritis.

The clinical improvement described in the study was supported by laboratory evidence of reduced inflammation.

The authors found that adverse effects of the treatment were mainly mild to moderate.

Alain Moussy from AB Science, a pharmaceutical company who are developing masitinib for multiple indications in human and animal medicine, said: "This is a milestone article for us, being the first publication of masitinib in a human study."

Moussy added: "Our preclinical studies have shown that masitinib selectively targets cell receptors known to be involved in various disease processes but does not affect those associated with toxicity, particularly cardiotoxicity."

Source: ANI


Recommended Reading

Latest Research News

 Carrying Alzheimer's Disease Genes May Increase the Risk of Developing Epilepsy
Is there a link between epilepsy and Alzheimer's disease? Yes, certain genes associated with Alzheimer's disease may increase the risk of developing epilepsy.
Insomnia Drug Class may Not Increase Exacerbation Risks
More research is needed to understand the risks of hypnotics among COPD patients and then optimize treatment strategies.
New Treatment Protocol for Brain Hemorrhage
Among hemorrhage patients, combination treatment protocol compared to usual care reduced poor functional outcomes.
How Can Life Stressors Affect Multiple Sclerosis Flares?
Life stressors were found to lead to multiple sclerosis, revealed study.
 High-Sugar Diet Damaging the Gut May Worsen Inflammatory Bowel Disease (IBD)
Diet containing increased amounts of sugar may interrupt the function of resident intestinal stem cells (ISCs) that maintain gut lining after inflammatory damage.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Successful Clinical Trials For New Rheumatoid Arthritis Drug Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests